A critical evaluation of the cardiac toxicity of citalopram: Part 2

Journal of Psychosocial Nursing and Mental Health Services

Volumn 49, Issue 12, 2011, Pages 13-16

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83655167429     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20111102-04     Document Type: Article

References (14)

1. Brown, A.D., Barton, D.A., & Lambert, G.W. (2009). Cardiovascular abnormalities in patients with major depressive disorder: Autonomic mechanisms and implications for treatment. CNS Drugs, 23, 583-602.
2. de Leon, J. (2007). The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19. Journal of Clinical Psychopharmacology, 27, 241-245.
3. ® (citalopram hydrobromide) tablets/ oral solution. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020822s038s040,021046s016s017lbl.pdf
4. Hintsa, T., Keltikangas-Järvinen, L., Puttonen, S., Ravaja, N., Toivonen, L., Kontula, K., & Swan, H. (2009). De-pressive symptoms in the congenital long QT syndrome. Annals of Medicine, 41, 516-521.
5. Howland, R.H. (2011). A critical evaluation of the cardiac toxicity of citalopram: Part 1. Journal of Psychosocial Nursing and Mental Health Services, 49(11), 13-16.
6. Kingbäck, M., Carlsson, B., Ahlner, J., Bengtsson, F., & Kugelberg, F.C. (2011). Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: In vivo studies in Sprague-Dawley and Dark Agouti rats. Chirality, 23, 172-177. doi: 10.1002/ chir.20901
7. Le Bloc'h, Y., Woggon, B., Weissenrieder, H., Brawand-Amey, M., Spagnoli, J., Eap, C.B., & Baumann, P. (2003). Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. Therapeutic Drug Monitoring, 25, 600-608.
8. Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M.A., van Zyl, L.T., Baker, B., Guertin, M.C. (2007). Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. Journal of the American Medical Association, 297, 367-379.
9. Minoretti, P., Politi, P., Martinelli, V., Emanuele, E., Bertona, M., Falcone, C., & Geroldi, D. (2006). QT interval duration in apparently healthy men is associated with depression-related personality trait neuroticism. Journal of Psychosomatic Research, 61, 19-23.
10. Montgomery, S.A. (1995). Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: Studies with citalopram. International Clinical Psychopharmacology, 10(Suppl. 1), 23-27.
11. Santangelo, A., Testaì, M., Barbagallo, P., Crisafulli, C., Grasso, S., Manuele, S. Maugeri, D. (2009). Use of specific serotonin reuptake inhibitors (SSRIs) (sertraline or citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly: Evidence from a Sicilian population >80 years recovered in the assisted sanitary residences (RSA). Archives of Gerontology and Geriatrics, 48, 350-352.
12. Sher, Y., Lolak, S., & Maldonado, J.R. (2010). The impact of depression in heart disease. Current Psychiatry Reports, 12, 255-264.
13. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Fava, M. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. American Journal of Psychiatry, 163, 28-40.
14. U.S. Food and Drug Administration. (2011). FDA drug safety communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Retrieved from http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm